Mariana Avalos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mariana Avalos has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Alexander T. Bakker
Department of Molecular Physiology, Leiden Institute of Chemistry, Leiden University, Leiden, The Netherlands
1 shared publication- Antonius P. A. Janssen
Leiden University
1 shared publication Berend Gagestein
Department of Molecular Physiology, Leiden Institute of Chemistry, Leiden University, Leiden, The Netherlands
1 shared publicationBing Liu
Department of Molecular Physiology, Leiden Institute of Chemistry, Leiden University, Leiden, The Netherlands
1 shared publicationConstant A. A. van Boeckel
Department of Molecular Physiology, Leiden Institute of Chemistry, Leiden University, Leiden, The Netherlands
1 shared publication- Cornelis J. Slingerland
Biological Chemistry Group, Institute of Biology Leiden, Leiden University, Sylviusweg 72, 2333 BE Leiden, The Netherlands
1 shared publication
Latest Publications
- Open Access
- 19 June 2024
- Published by Springer Nature in Nature Chemistry
- Vol. 16 (9) , 1462-1472
Discovery of isoquinoline sulfonamides as allosteric gyrase inhibitors with activity against fluoroquinolone-resistant bacteria
Bacteria have evolved resistance to nearly all known antibacterials, emphasizing the need to identify antibiotics that operate via novel mechanisms. Here we report a class of allosteric inhibitors of DNA gyrase with antibacterial activity against fluoroquinolone-resistant clinical isolates of Escherichia coli. Screening of a small-molecule library revealed an initial isoquinoline sulfonamide hit, which was optimized via medicinal chemistry efforts to afford the more potent antibacterial LEI-800. Target identification studies, including whole-genome sequencing of in vitro selected mutants with resistance to isoquinoline sulfonamides, unanimously pointed to the DNA gyrase complex, an essential bacterial topoisomerase and an established antibacterial target. Using single-particle cryogenic electron microscopy, we determined the structure of the gyrase–LEI-800–DNA complex. The compound occupies an allosteric, hydrophobic pocket in the GyrA subunit and has a mode of action that is distinct from the clinically used fluoroquinolones or any other gyrase inhibitor reported to date. LEI-800 provides a chemotype suitable for development to counter the increasingly widespread bacterial resistance to fluoroquinolones.
- 19 June 2024
- Published by Springer Nature in Nature Chemistry
- Vol. 16 (9) , 1462-1472
Open AccessDiscovery of isoquinoline sulfonamides as allosteric gyrase inhibitors with activity against fluoroquinolone-resistant bacteria
Bacteria have evolved resistance to nearly all known antibacterials, emphasizing the need to identify antibiotics that operate via novel mechanisms. Here we report a class of allosteric inhibitors of DNA gyrase with antibacterial activity against fluoroquinolone-resistant clinical isolates of Escherichia coli. Screening of a small-molecule library revealed an initial isoquinoline sulfonamide hit, which was optimized via medicinal chemistry efforts to afford the more potent antibacterial LEI-800. Target identification studies, including whole-genome sequencing of in vitro selected mutants with resistance to isoquinoline sulfonamides, unanimously pointed to the DNA gyrase complex, an essential bacterial topoisomerase and an established antibacterial target. Using single-particle cryogenic electron microscopy, we determined the structure of the gyrase–LEI-800–DNA complex. The compound occupies an allosteric, hydrophobic pocket in the GyrA subunit and has a mode of action that is distinct from the clinically used fluoroquinolones or any other gyrase inhibitor reported to date. LEI-800 provides a chemotype suitable for development to counter the increasingly widespread bacterial resistance to fluoroquinolones.